Physician profile
Ronan Monsef
NPI 1528132594
$1,408.25
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $302 · 2021: $61.81 · 2022: $73.88 · 2023: $90.66 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $261.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $313.65 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $259.31 | 2019-2023 | |
| Amarin Pharma, INC. | $213.70 | 2019-2020 | |
| Icotec Medical INC. | $171.12 | 2024 | Vader Pedicle System |
| Hikma Pharmaceuticals USA | $119.83 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.03 | 2019-2022 | |
| Pfizer INC. | $71.32 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.70 | 2019-2020 | |
| Allergan, INC. | $25.57 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.48 | 2021 | |
| Genentech USA, INC. | $21.53 | 2019 | |
| Bausch Health US, LLC | $17.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.43 | 2019 | |
| Amgen INC. | $15.00 | 2019 | |
| Glaxosmithkline, LLC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronan Monsef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.